The Greater Montreal Chapter of Women In Bio will present a half-day conference followed by a keynote lunch on the latest developments and trends affecting market access and reimbursement of drugs and other healthcare technologies in Quebec, from 8:30 a.m. – 1:30 p.m., Thursday, April 16, 2015, at the NEOMED Institute.
The increasing costs of healthcare, including the cost of new specialty and orphan drugs, are putting an unprecedented strain on the Quebec healthcare system. In an effort to control drug expenditure while optimizing access and reimbursement to novel drugs, the Quebec government has decided to make product listing agreements (PLAs) possible through Bill 28, thus aligning itself with other Canadian provinces which have been allowing PLAs for close to a decade.
Join our PDCI women in bio presenters Kaitlyn Proulx (Director, Pricing and Market Access) and Nancy Paul Roc (Associate Director, Pricing and Market Access) discuss ‘New trends in market access and reimbursement’ alongside other great women in bio such as Mélanie Bourassa Forcier (Professor at the Université of Sherbrooke and Lawyer), Michelle Savoie (CEO of Montréal InVivo and Professor at the Faculty of Pharmacy of Université de Montréal), Ranya El-Masri (Director Government Affairs at Merck), Denise Cloutier (National Director, Health & Economic Policy at Pfizer), Gail Ouellette (CEO of Quebec Coalition of Orphan Diseases), Claude Di Stasio (Vice-President Quebec Affairs, Canadian Life and Health Insurance Industry (CLHIA)), and Carole Marcotte, (Director of Drug evaluation for listing, Institut national d’excellence en santé et en services sociaux (INESSS)) engage the crowd on these hot topics.
For more information, please visit the Women In Bio website.